Evidence map›Paper›PMID 21671175›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2011

Role of RANTES and its receptor in gastric cancer metastasis.

Zhixin Cao, Xiangshang Xu, Xuelai Luo, Li Li, Bin Huang, Xiaolan Li, Deding Tao, Junbo Hu, Jianping Gong

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer.International journal of general medicine · 2020
    Article
  11. Observational
  12. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.International journal of molecular sciences · 2018
    Review
  13. C-C motif chemokine receptors in gastric cancer.Molecular and clinical oncology · 2018
    Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhixin CaoGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiangshang XuGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xuelai LuoGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Li LiCancer Biology Research Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Bin HuangOut-patient Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiaolan LiGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Deding TaoGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Junbo HuGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China.
Jianping GongGastrointestinal Surgery Center, Huazhong University of Science and Technology, Wuhan, 430030, China. jpgong@tjh.tjmu.edu.cn.
Huazhong University of Science and Technology · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study examined the role of regulated upon activation normal T cell expressed and secreted (RANTES) and its receptor C-C chemokine receptor type 5 (CCR5) in gastric cancer metastasis and the associated mechanism. The expression of RANTES and CCR5 was detected by using immunohistochemical staining and Western blotting in the gastric cancer tissues obtained from 60 gastric cancer patients with or without lymph node metastasis (n=30 in each). The results showed that the expression levels of RANTES and CCR5 were higher in gastric cancer with lymph node metastasis than in that without metastasis (P<0.05). The expression levels of RANTES in 30 lymph nodes with cancerous invasion were higher than in 30 normal lymph nodes (P<0.05). Chemotactic test revealed that the number of migrating gastric cancer cells (n=295.0 ± 54.6) induced by the protein of cancer-invading lymph nodes was greater than that by the protein mixture from cancer-invading lymph nodes and RANTES antibody (n=42.5 ± 11.6) (P<0.05). RT-PCR showed that the expression levels of the main Th1 cytokines (IL-2, Γ-IFN) were lower in gastric cancer with lymph node metastasis (2.22 ± 0.90, 3.26 ± 1.15 respectively) than in that without metastasis (3.07 ± 1.67, 4.77 ± 1.52 respectively) (P<0.05), but the expression level of the main Th 2 cytokine (IL-10) was higher in gastric cancer with lymph nodes metastasis (6.06 ± 2.04) than in that without metastasis (4.88 ± 1.87) (P<0.05). It was concluded that RANTES and its receptor CCR5 may contribute to gastric cancer metastasis through influencing the balance of Th1/Th2. RANTES and CCR5 may become a marker of gastric cancer metastasis.

Indexed as

Th1-Th2 BalanceAgedBiomarkers, TumorChemokine CCL5FemaleHumansLymphatic MetastasisMaleMiddle AgedReceptors, CCR5Stomach NeoplasmsBiomarkers, TumorCCL5 protein, humanChemokine CCL5Receptors, CCR5

Identifiers

PMID21671175
OpenAlexW1565568215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.